Skip to NavigationSkip to content

Yervoy

Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma

Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line treatment of unresectable malignant pleural mesothelioma, a potentially life-threatening lung cancer caused by asbestos fibre insulation, and one that sees around 20,000 new diagnoses a year in the US.

The combo was tested in 605 participants, with each receiving fortnightly intravenous infusions of Opdivo alongside intravenous infusions of Yervoy every six weeks for up to two years, or until disease progression or unacceptable toxicity wa

Bristol-Myers Squibb demonstrates potential for long-term survival in kidney cancer patients treated with Opdivo plus Yervoy

Bristol-Myers Squibb has announced updated results from trialing Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

The results came from the Phase 3 CheckMate-214 study. With a follow-up of 42 months, the combination of Opdivo plus Yervoy yielded superior overall survival (OS), objective response rates, duration of response and complete response (CR) rates for intermediate/poor-risk (IP) patients compared to patients treated with sunitinib alone.

BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer

Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of advanced non-small cell lung cancer (NSCLC).

The decision was made after the EMA’s Committee for Medicinal Products for Human Use (CHMP) informed the company that the data had submitted was not valid due to a number of “protocol changes” that had been made during the execution of the clinical study which generated them.

BMS' Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that the drug, when combined with Yervoy (ipilimumab) and two cycles of chemotherapy, met its primary endpoint for the first-line treatment of advanced non-small cell lung cancer (NSCLC).

At a pre-specified analysis, the results illustrated that the combo showed superior overall survival benefit in relation to its comparator, chemotherapy monotherapy for up to four cycles followed by optional maintenance therapy.

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to patients in England via the Cancer Drugs Fund (CDF) for the first-line treatment of untreated renal cell carcinoma (RCC), the most common form of kidney cancer.

The drug’s immediate availability through this new pathway provides RCC with another treatment option, which is particularly meaningful as current NHS standard of treatment such as pazopanib, sunitinib, tivozanib or cabozantinib are associated with side-effects including hand and

Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application

Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer.

The US firm withdrew the marketing application for the combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab), after a request from the FDA for more data.

As the marketing application cannot be delayed, BMS was forced to withdraw the marketing application and will re-file later.

BMS' Opdivo+Yervoy combo fails in small cell lung cancer

Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage small cell lung cancer (SCLC) without disease progression following the completion of first-line platinum-based chemotherapy.

Compared to placebo, the manufacturer said that its PD-1 inhibitor/CTLA-4 inhibitor combo failed to improve the Phase 3 trial’s primary endpoint of overall survival compared to placebo.

BMS' Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with Opdivo in combination with Yervoy, survived four years or more.

The findings demonstrate the two drugs are more effective in combination than either is alone. While 46% of patients taking Opdivo and 30% of those taking Yervoy survived for four years or longer, the findings demonstrated that more than half survived 48 months when the two drugs were combined.

BMS' Opdivo+Yervoy combo secures FDA approval in kidney cancer

The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers Squibb, for the treatment of previously untreated advanced renal cell carcinoma which is of intermediate or poor risk.

BMS' Opdivo and Yervoy combo better than chemo in halting lung cancer progression

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in patients whose cancers have a high tumour mutation burden (TMB), regardless of PD-L1 expression.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches